selected publications
-
Clonal Hematopoiesis and Premalignant Diseases.
Cold Spring Harbor perspectives in medicine.
2020
Review
GET IT
Times cited: 12 -
Cranberry A-type proanthocyanidins selectively target acute myeloid leukemia cells.
Blood advances.
2019
Academic Article
GET IT
Times cited: 5 -
Clonal Hematopoiesis and risk of Acute Myeloid Leukemia.
Best practice & research. Clinical haematology.
2019
Information Resource
GET IT
Times cited: 7 -
Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance).
Blood advances.
2018
Academic Article
GET IT
Times cited: 37 -
Somatic mutations precede acute myeloid leukemia years before diagnosis.
Nature medicine.
2018
Academic Article
GET IT
Times cited: 424 -
Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia.
Haematologica.
2018
Academic Article
GET IT
Times cited: 32 -
Single-cell RNA sequencing reveals a signature of sexual commitment in malaria parasites.
Nature.
2017
Academic Article
GET IT
Times cited: 147 -
Selection and characterization of antibody clones are critical for accurate flow cytometry-based monitoring of CD123 in acute myeloid leukemia.
Leukemia & lymphoma.
2017
Letter
GET IT
Times cited: 12 -
CD25 expression and outcomes in older patients with acute myelogenous leukemia treated with plerixafor and decitabine.
Leukemia & lymphoma.
2017
Academic Article
GET IT
Times cited: 11 -
Myelodysplastic Syndrome, Unclassifiable (MDS-U) With 1% Blasts Is a Distinct Subgroup of MDS-U With a Poor Prognosis.
American journal of clinical pathology.
2017
Academic Article
GET IT
Times cited: 15 -
Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
2017
Academic Article
GET IT
Times cited: 33 -
The effect of initial molecular profile on response to recombinant interferon-α (rIFNα) treatment in early myelofibrosis.
Cancer.
2017
Academic Article
GET IT
Times cited: 28 -
Minimal Residual Disease Monitoring of Acute Myeloid Leukemia by Massively Multiplex Digital PCR in Patients with NPM1 Mutations.
The Journal of molecular diagnostics : JMD.
2017
Academic Article
GET IT
Times cited: 71 -
Identification of a nucleoside analog active against adenosine kinase-expressing plasma cell malignancies.
The Journal of clinical investigation.
2017
Academic Article
GET IT
Times cited: 7 -
Minimal residual disease in acute myelogenous leukemia.
International journal of laboratory hematology.
2017
Information Resource
GET IT
Times cited: 39 -
Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers.
Cancer discovery.
2017
Academic Article
GET IT
Times cited: 97 -
Matrix stiffening promotes a tumor vasculature phenotype.
Proceedings of the National Academy of Sciences of the United States of America.
2016
Academic Article
GET IT
Times cited: 297 -
Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia.
Nature medicine.
2016
Academic Article
GET IT
Times cited: 288 -
Selective activity of the histone deacetylase inhibitor AR-42 against leukemia stem cells: a novel potential strategy in acute myelogenous leukemia.
Molecular cancer therapeutics.
2014
Academic Article
GET IT
Times cited: 51 -
Novel mTOR inhibitory activity of ciclopirox enhances parthenolide antileukemia activity.
Experimental hematology.
2013
Academic Article
GET IT
Times cited: 33 -
Gene signature critical to cancer phenotype as a paradigm for anticancer drug discovery.
Oncogene.
2012
Academic Article
GET IT
Times cited: 5 -
Gene sets identified with oncogene cooperativity analysis regulate in vivo growth and survival of leukemia stem cells.
Cell stem cell.
2012
Academic Article
GET IT
Times cited: 50 -
Acute myelogenous leukemia stem cells: from Bench to Bedside.
Cancer letters.
2012
Information Resource
GET IT
Times cited: 42 -
Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways.
Blood.
2010
Academic Article
GET IT
Times cited: 64 -
Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data.
Blood.
2008
Academic Article
GET IT
Times cited: 167 -
An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells.
Blood.
2007
Academic Article
GET IT
Times cited: 354 -
Tat-calpastatin fusion proteins transduce primary rat cortical neurons but do not inhibit cellular calpain activity.
Experimental neurology.
2004
Academic Article
GET IT
Times cited: 22 -
Interactions of Campylobacter jejuni cytolethal distending toxin subunits CdtA and CdtC with HeLa cells.
Infection and immunity.
2003
Academic Article
GET IT
Times cited: 103 -
Campylobacter jejuni cytolethal distending toxin promotes DNA repair responses in normal human cells.
Infection and immunity.
2003
Academic Article
GET IT
Times cited: 87 -
Cytolethal distending toxin demonstrates genotoxic activity in a yeast model.
Infection and immunity.
2001
Academic Article
GET IT
Times cited: 63